Company / Total Debt
UroGen Pharma Ltd. Total Debt History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$125.0M
FY2025
5-year range
$0 / $125.0M
FY2021-FY2025
Trend
+2.7%
vs FY2024
Sector context
#51 of 83
Health Care
What the data says
At $125M, UroGen Pharma Ltd.'s total debt ranks #33 of 83 in the Health Care sector. Total Debt has increased for 4 consecutive years, from $0 in FY2021 to $125M in FY2025.
Based on SEC 10-K filings.
$125M in FY2025 with a 3-year CAGR of +8.6%.
Increased from $99M to $125M over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- +8.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#33 of 83 in Health CareTop 39% of 83This company $125.0M Sector average $6.2B
▼
-98.0% below sector average
Key checks
Key Insights
- UroGen Pharma Ltd.'s total debt has grown for 3 consecutive years.
- 3-year CAGR of +8.6%, indicating consistent growth.
- In FY2025, total debt increased 2.7% year-over-year.
- Ranks #51 out of 83 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $125.0M | +2.7% |
| FY2024 | $121.7M | +23.5% |
| FY2023 | $98.6M | +1.0% |
| FY2022 | $97.5M | - |
| FY2021 | $0 | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026